0001209191-17-035186.txt : 20170524
0001209191-17-035186.hdr.sgml : 20170524
20170524211324
ACCESSION NUMBER: 0001209191-17-035186
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170522
FILED AS OF DATE: 20170524
DATE AS OF CHANGE: 20170524
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revance Therapeutics, Inc.
CENTRAL INDEX KEY: 0001479290
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770551645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7555 GATEWAY BLVD.
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-742-3400
MAIL ADDRESS:
STREET 1: 7555 GATEWAY BLVD.
CITY: NEWARK
STATE: CA
ZIP: 94560
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Browne L Daniel
CENTRAL INDEX KEY: 0001597583
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36297
FILM NUMBER: 17868089
MAIL ADDRESS:
STREET 1: 7555 GATEWAY BOULEVARD
CITY: NEWARK
STATE: CA
ZIP: 94560
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-05-22
0
0001479290
Revance Therapeutics, Inc.
RVNC
0001597583
Browne L Daniel
C/O REVANCE THERAPEUTICS, INC.
7555 GATEWAY BOULEVARD
NEWARK
CA
94560
1
1
0
0
CEO and President
Common Stock
2017-05-22
4
S
0
12287
20.1969
D
183932
D
Common Stock
2017-05-24
4
S
0
19713
20.3465
D
164219
D
Common Stock
409
I
See footnote
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Browne.
The shares were disposed to satisfy tax withholding obligations that arose in connection with the vesting of 32,000 shares of restricted stock on May 19, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.99 to $20.20. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.65. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.
/s/ Gordon Ho, Attorney-in-Fact
2017-05-24